Operator

Welcome to the conference call. [Operator Instructions]. Now I will hand the conference over to the speakers. Please go ahead.

Markus Rohrwild
Chief Executive Officer

Good morning, everybody. Welcome to our Q1 investor call. I will go through a couple of highlights of the first quarter and then hand over to the team to continue. A quick reminder, Gubra operates via a business model involving 3 distinct but synergistic business units. We have our biotech unit where we discover and develop peptide therapeutics, and we have a validated platform with multiple obesity assets in clinical development. We have our CRO where we provide preclinical research services to external and internal customers. And we have also now established Gubra Ventures, where we invest in high-quality science adjacent to our core areas.

Given I've recently received questions, I also want to be clear that Gubra Ventures is not a corporate venture fund. Coming out a record year 2025. We have started 2026 with great momentum in our biotech pipeline. A few recent events. In the beginning of the year, we have started to expand our facilities here in Boston at the DTU Science Park. So we are significantly expanding our lab facilities, which is beneficial to our internal discovery group as well as our CRO that we can do more studies in the future. We have strengthened our clinical leadership with